149 related articles for article (PubMed ID: 21689426)
1. Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.
Arienti C; Tesei A; Verdecchia GM; Framarini M; Virzì S; Grassi A; Scarpi E; Turci L; Silvestrini R; Amadori D; Zoli W
J Transl Med; 2011 Jun; 9():94. PubMed ID: 21689426
[TBL] [Abstract][Full Text] [Related]
2. Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer.
Arienti C; Tesei A; Verdecchia GM; Framarini M; Virzì S; Grassi A; Scarpi E; Turci L; Silvestrini R; Amadori D; Zoli W
Clin Colorectal Cancer; 2013 Jun; 12(2):122-7. PubMed ID: 23332421
[TBL] [Abstract][Full Text] [Related]
3. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
4. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.
Sawers L; Ferguson MJ; Ihrig BR; Young HC; Chakravarty P; Wolf CR; Smith G
Br J Cancer; 2014 Sep; 111(6):1150-8. PubMed ID: 25010864
[TBL] [Abstract][Full Text] [Related]
5. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
6. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
Zhao D; Zhang W; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):196-200. PubMed ID: 22780973
[TBL] [Abstract][Full Text] [Related]
7. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
8. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
Ferriss JS; Kim Y; Duska L; Birrer M; Levine DA; Moskaluk C; Theodorescu D; Lee JK
PLoS One; 2012; 7(2):e30550. PubMed ID: 22348014
[TBL] [Abstract][Full Text] [Related]
9. [Primary drug resistance/sensitivity in vitro and clininical outcome in ovarian cancer patients].
Sedláková I; Tosner J; Cervinka M; Brigulová K; Rezác A; Spacek J; Laco J; Skapinec P
Ceska Gynekol; 2011 Jun; 76(3):184-9. PubMed ID: 21838147
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells.
Poulain L; Sichel F; Crouet H; Bureau F; Gauduchon P; Gignoux M; Le Talaër JY
Cancer Chemother Pharmacol; 1997; 40(5):385-90. PubMed ID: 9272114
[TBL] [Abstract][Full Text] [Related]
11. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
12. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
13. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
Zamagni C; Wirtz RM; De Iaco P; Rosati M; Veltrup E; Rosati F; Capizzi E; Cacciari N; Alboni C; Bernardi A; Massari F; Quercia S; D'Errico Grigioni A; Dietel M; Sehouli J; Denkert C; Martoni AA
Endocr Relat Cancer; 2009 Dec; 16(4):1241-9. PubMed ID: 19749010
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
[TBL] [Abstract][Full Text] [Related]
15. AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.
Li C; Liu J; Lu R; Yu G; Wang X; Zhao Y; Song H; Lin P; Sun X; Yu X; Zhang Y; Ning X; Geng J
Int J Gynecol Cancer; 2011 May; 21(4):602-8. PubMed ID: 21543927
[TBL] [Abstract][Full Text] [Related]
16. [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
Bogush TA; Popova AS; Dudko EA; Bogush EA; Tyulyandina AS; Tyulyandin SA; Davydov MI
Antibiot Khimioter; 2015; 60(3-4):42-50. PubMed ID: 26415382
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response.
Nakada S; Aoki D; Ohie S; Horiuchi M; Suzuki N; Kanasugi M; Susumu N; Udagawa Y; Nozawa S
Int J Gynecol Cancer; 2005; 15(3):445-52. PubMed ID: 15882168
[TBL] [Abstract][Full Text] [Related]
18. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T
Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041
[TBL] [Abstract][Full Text] [Related]
19. Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.
Guardiola E; Delroeux D; Heyd B; Combe M; Lorgis V; Demarchi M; Stein U; Royer B; Chauffert B; Pivot X
World J Surg Oncol; 2009 Feb; 7():14. PubMed ID: 19203351
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
